Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access